THC Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Tenet Healthcare Corp's (THC) financials, detailing its revenue breakdown, profitability margins, and competitor comparison. The largest portion of its revenue comes from hospital operations, while it maintains strong gross and operating margins. The article also benchmarks THC against competitors like UHS and CHE, highlighting its market position and efficiency.
Allspring Global Investments Holdings LLC Has $68.69 Million Stock Holdings in Tenet Healthcare Corporation $THC
Allspring Global Investments Holdings LLC reduced its stake in Tenet Healthcare Corporation (NYSE:THC) by 14.9% in Q4, now holding 344,388 shares valued at $68.69 million. Other hedge funds also adjusted their positions, and institutional investors own 95.44% of the company's stock. Analysts generally maintain a "Moderate Buy" rating with an average price target of $250.56, following strong Q4 earnings where Tenet Healthcare exceeded EPS and revenue estimates and provided positive FY2026 guidance.
THC Technical Analysis | Trend, Signals & Chart Patterns | TENET HEALTHCARE CORP (NYSE:THC)
TENET HEALTHCARE CORP (NYSE:THC) has a technical rating of 2 out of 10, indicating negative short and long-term trends despite outperforming 79% of all stocks in the past year. The stock is currently trading near the lows of its wide monthly range and shows signs of being oversold according to RSI and Stochastics. Investors are advised to wait for consolidation due to volatile price movement.
New Tenet Healthcare (NYSE: THC) controller to receive $475k salary
Tenet Healthcare announced changes in its accounting leadership, with R. Scott Ramsey retiring as Senior Vice President & Controller and Principal Accounting Officer effective April 30, 2026, and remaining on part-time for transition support. J. Michael Grooms has been appointed as the new Senior Vice President & Controller, effective April 6, 2026, and will become Principal Accounting Officer on May 1, 2026. Grooms' compensation package includes a $475,000 annual base salary, a target cash bonus, and significant equity grants.
Guggenheim Lifts Tenet Healthcare (THC) Price Target to $283
Guggenheim raised its price target for Tenet Healthcare Corporation (THC) to $283 from $271, maintaining a Buy rating due to an "easy set-up" for the first quarter and manageable projected core EBITDA growth. Concurrently, Mizuho also increased its price target for THC to $265 from $235, citing potential benefits from a positive demographic shift and a focus on higher-acuity surgeries. The company, founded in 1969, operates through Hospital Operations and Ambulatory Care segments.
Tenet sets April 30 release for Q1 results, call at 10 a.m. ET
Tenet Healthcare Corporation (NYSE: THC) announced that it will release its first-quarter 2026 results before the market opens on Thursday, April 30, 2026. This will be followed by a conference call at 10:00 a.m. Eastern Time. Investors can access a live webcast and audio archive of the call via the investor relations section of Tenet's website.
Tenet appoints J. Michael Grooms as SVP & Controller; R. Scott Ramsey to retire
Tenet Healthcare has appointed J. Michael Grooms as Senior Vice President & Controller, succeeding R. Scott Ramsey who is set to retire on April 30, 2026. Ramsey will continue part-time until March 31, 2028, ensuring a smooth transition. Grooms, who previously served as SVP and Chief Accounting Officer at Lifepoint, will assume the Principal Accounting Officer role effective May 1, 2026, with a base salary of $475,000 and additional compensation details outlined.
Assenagon Asset Management S.A. Lowers Stock Holdings in Tenet Healthcare Corporation $THC
Assenagon Asset Management S.A. significantly reduced its stake in Tenet Healthcare Corporation by 82.7% in the fourth quarter of 2025. Despite this sale, other major institutional investors, including Norges Bank and Eminence Capital LP, substantially increased their positions, leading to 95.44% institutional ownership. Tenet Healthcare reported strong Q4 earnings, beating estimates, and analysts maintain a "Moderate Buy" rating with a target price of $250.56.
Vanguard disaggregates holdings; Tenet Healthcare (NYSE: THC) shows 0% ownership
The Vanguard Group filed an Amendment No. 16 to a Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of Tenet Healthcare Corp common stock. This change is due to an internal realignment where Vanguard subsidiaries will now report beneficial ownership separately, as described under SEC Release No. 34-39538. The filing indicates that The Vanguard Group, Inc. no longer beneficially owns securities held by those subsidiaries, shifting reporting responsibility to individual Vanguard affiliates.
Tenet Healthcare Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
Tenet Healthcare Corp. has seen its stock evaluation revised amidst market dynamics, with its stock price showing volatility, currently at $200.35. Despite mixed technical indicators, the company has significantly outperformed the S&P 500 over one, three, and five-year periods, demonstrating strong returns. Its stock performance over the past year surged by 59.86%, highlighting its resilience and growth potential.
Investors Are Actively Looking Into Tenet Healthcare Corporation (THC): Essential Information You Should Be Aware Of
Tenet Healthcare (THC) has seen its shares decline by 10.1% in the last month, though its sector also dropped. The article delves into fundamental drivers such as earnings estimate revisions, revenue growth projections, and recent financial results. Tenet holds a Zacks Rank #3 (Hold) and a Zacks Value Style Score of "A", suggesting it is currently trading at a discount.
Tenet Healthcare wins legal victory over ‘unfair and deceptive’ hospital safety grades
Tenet Healthcare has won a legal victory against The Leapfrog Group regarding its hospital safety grades, with a U.S. District Judge ruling Leapfrog's methodology unscientific and a deceptive business practice. The ruling ordered Leapfrog to remove poor grades for five South Florida hospitals owned by Tenet, which had refused to participate in Leapfrog's data requests. Leapfrog plans to appeal the decision, arguing it threatens transparency and First Amendment rights, and will amend its practices by removing grades for hundreds of non-participating hospitals.
THC SEC Filings - Tenet Healthcare Corp 10-K, 10-Q, 8-K Forms
This page provides access to Tenet Healthcare Corporation's SEC filings (Ticker: THC), including 10-K, 10-Q, 8-K, and insider trading forms. It offers AI-powered summaries of these documents, highlighting key events like debt refinancing, board changes, and insider stock transactions. The article also provides a brief overview of Tenet's business segments and financial data.
Tenet Healthcare Corporation (NYSE:THC) Given Average Rating of "Moderate Buy" by Brokerages
Tenet Healthcare Corporation (NYSE:THC) has received an average "Moderate Buy" rating from 22 analysts, with a consensus one-year price target of $250.56. The company recently reported strong quarterly earnings, beating expectations, and provided positive FY2026 guidance. Despite some insider selling, institutional investors and hedge funds maintain a significant ownership stake in the healthcare services firm.
Investors Are Actively Looking Into Tenet Healthcare Corporation (THC): Essential Information You Should Be Aware Of
Tenet Healthcare (THC) is drawing investor attention, with recent stock performance showing a 10.1% decline in the last month against broader market and sector drops. The article highlights the importance of underlying fundamentals like earnings estimate revisions, revenue growth projections, and valuation analysis for long-term investment decisions. Currently, Tenet holds a Zacks Rank #3 (Hold), suggesting it will perform in line with the broader market in the near term, with a Value Style Score of "A" indicating it might be trading at a discount.
Tenet Healthcare Corporation $THC is Cambria Investment Management L.P.'s 7th Largest Position
Cambria Investment Management L.P. reduced its stake in Tenet Healthcare Corporation (THC) by 6.3% in the third quarter, making it their 7th largest holding. Despite this, Tenet Healthcare recently beat earnings expectations and holds a "Moderate Buy" consensus rating from analysts. Insider selling has been noted, but institutional ownership remains high at 95.44%.
Livforsakringsbolaget Skandia Omsesidigt Invests $3.77 Million in Tenet Healthcare Corporation $THC
Livforsakringsbolaget Skandia Omsesidigt has acquired a new position in Tenet Healthcare Corporation (NYSE:THC) during the third quarter, purchasing 18,600 shares valued at approximately $3.77 million. Other institutional investors have also adjusted their holdings in Tenet Healthcare, which currently has a "Moderate Buy" rating from analysts with a consensus price target of $250.56. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue.
Fred Alger Management LLC Trims Holdings in Tenet Healthcare Corporation $THC
Fred Alger Management LLC significantly reduced its stake in Tenet Healthcare Corporation by 29.7% in Q3, selling over 41,000 shares. Despite this, insider selling has also been noted, with executives selling shares worth over $10 million in the past 90 days. Analysts remain largely optimistic, with several firms raising their price targets, and Tenet Healthcare recently surpassed Q3 earnings expectations.
Alliancebernstein L.P. Sells 38,078 Shares of Tenet Healthcare Corporation $THC
Alliancebernstein L.P. recently reduced its stake in Tenet Healthcare Corporation by 4.8%, selling 38,078 shares and now owning 752,176 shares valued at $152.72 million. Despite this trimming, other institutional investors like Boston Partners and Ameriprise Financial Inc. increased their holdings. Analysts maintain a "Moderate Buy" rating for Tenet Healthcare, with an average price target of $250.56, while company insiders have also sold shares totaling over $10 million in the past ninety days.
Ameriprise Financial Inc. Sells 283,312 Shares of Tenet Healthcare Corporation $THC
Ameriprise Financial Inc. reduced its stake in Tenet Healthcare Corporation by 13.4% in the third quarter, selling 283,312 shares and now owning 1,836,111 shares valued at $372.8 million. Other institutional investors have also adjusted their holdings, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $250.56. Tenet Healthcare recently reported strong earnings, exceeding analyst expectations, and has seen significant insider selling activity.
Tenet Healthcare shares slide 3.7% amid apparent profit-taking after recent highs
Tenet Healthcare (THC) shares slid 3.7% today, likely due to profit-taking after a recent strong rally that followed upbeat full-year 2025 results and a positive 2026 outlook. The decline does not appear to be driven by any new negative headlines, but rather by trading dynamics and potential recalibration of valuations by investors. Insider trading data shows 18 sales and zero purchases of THC stock in the last six months, while hedge funds showed mixed activity in Q4 2025.
Iron Triangle Partners LP Has $27.91 Million Stock Holdings in Tenet Healthcare Corporation $THC
Iron Triangle Partners LP reduced its stake in Tenet Healthcare Corporation by 27.7%, now holding 137,448 shares valued at $27.91 million. Despite this, several other institutional investors increased their positions, with institutional ownership of Tenet Healthcare reaching 95.44%. Analysts maintain a "Moderate Buy" rating with an average price target of $250.56, following the company beating its quarterly EPS expectations and providing strong FY2026 guidance.
Farallon Capital Management LLC Reduces Stake in Tenet Healthcare Corporation $THC
Farallon Capital Management LLC decreased its stake in Tenet Healthcare Corporation by 21.7% in the third quarter, while several other institutional investors significantly increased or initiated new positions. Despite Farallon's reduction, institutional ownership remains high at 95.44%. Tenet Healthcare reported strong Q3 earnings, beating analyst expectations, and analysts currently rate the stock as a "Moderate Buy" with an average price target of $250.56.
Brevan Howard Capital Management LP Has $5.19 Million Stake in Tenet Healthcare Corporation $THC
Brevan Howard Capital Management LP reduced its stake in Tenet Healthcare Corporation by 32.7% in the third quarter, now owning 25,537 shares valued at $5.19 million. Despite this, other institutional investors significantly increased their holdings, with 95.44% of the company's stock owned by institutional investors and hedge funds. Tenet Healthcare's stock is trading at $227.79, and analysts have a "Moderate Buy" consensus rating with an average target price of $250.56.
Tenet Healthcare Corporation $THC Shares Purchased by Algert Global LLC
Algert Global LLC increased its stake in Tenet Healthcare Corporation (NYSE:THC) by 21.8% during the third quarter, bringing their total holdings to 50,379 shares valued at $10.23 million. This comes amidst broader institutional interest, with other hedge funds also boosting their positions in THC. Wall Street analysts maintain a "Moderate Buy" rating for Tenet Healthcare, with an average target price of $250.56, following positive earnings reports and revenue growth.
Tenet Healthcare EVP Sells Shares
Paola M. Arbour, EVP and Chief Information Officer of Tenet Healthcare Corp (THC), sold 6,500 shares of common stock for $1,549,795 on March 11, 2026. This transaction reduced her direct ownership in the company to 29,291 shares. The sale price averaged $238.43 per share.
[Form 4] TENET HEALTHCARE CORP Insider Trading Activity
Paola M. Arbour, EVP and Chief Information Officer of Tenet Healthcare Corp (THC), executed an open-market sale of 6,500 shares of common stock on March 11, 2026, at a weighted average price of $238.43 per share. This transaction reduced her direct holdings to 29,291 shares. The sale is characterized as a routine liquidity event rather than an indicator of a change in the company's business outlook.
[144] TENET HEALTHCARE CORP SEC Filing
Tenet Healthcare Corp (THC) filed a Form 144, indicating an intended sale of up to 6,500 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $1,549,773.55. The filing occurred on March 11, 2026, and also noted recent restricted stock vesting events totaling 6,500 shares related to compensation. Analysts viewed the filing as neutral, emphasizing that Form 144 is a notice of intent and not a confirmation of sale, and the quantity of shares is small relative to the company's outstanding shares.
Barclays PLC Sells 126,642 Shares of Tenet Healthcare Corporation $THC
Barclays PLC reduced its holdings in Tenet Healthcare Corporation by 49.2% in the third quarter, selling 126,642 shares and retaining 130,574 shares valued at $26.51 million. Despite this, other institutional investors have either increased their stakes or initiated new positions in the company. Analysts generally maintain a positive outlook on Tenet Healthcare, with a consensus "Moderate Buy" rating and an average target price of $247.67, following recent positive earnings and revenue reports.
Insider Selling: Thomas W Arnst Unloads $1.91M Of Tenet Healthcare Stock
Thomas W. Arnst, EVP at Tenet Healthcare, recently sold 8,000 shares of NYSE: THC stock, totaling $1.91 million. Tenet Healthcare, a Dallas-based healthcare services organization, demonstrated an 8.95% revenue growth rate as of December 31, 2025, but faces challenges with a high debt-to-equity ratio of 3.12. The article also details valuation metrics, such as a strong gross margin of 81.73%, an EPS of 4.24, and P/E, P/S, and EV/EBITDA ratios indicating potential undervaluation.
Tenet Healthcare EVP Sells 8,000 Shares
Thomas W. Arnst, EVP, Chief Admin. Officer & GC of Tenet Healthcare Corp (THC), sold 8,000 shares of company stock on March 9, 2026, for a total of $1,910,777. The sales were executed at weighted average prices of $238.42 and $239.46 per share. Following these transactions, Arnst directly owns 12 shares of Tenet Healthcare.
Insider Sell Alert: Thomas Arnst Sells 8,000 Shares of Tenet Hea
Thomas Arnst, Executive Vice President, Chief Administrative Officer & General Counsel at a subsidiary of Tenet Healthcare Corp (THC), recently sold 8,000 shares of the company, bringing his total ownership to 12 shares. This transaction is part of a pattern of insider selling, with Arnst having sold 41,786 shares over the past year and no insider buys recorded for the company in the same period. With shares trading at $238.85 against a GF Value of $149.76, the stock is considered significantly overvalued.
Tenet Healthcare (NYSE:THC) EVP Sells $1,910,800.00 in Stock
Tenet Healthcare's EVP, Thomas Arnst, sold 8,000 shares of the company's stock for $1,910,800.00, reducing his position by 99.85%. Despite this insider sale, analysts maintain a "Moderate Buy" consensus rating for THC, with the company recently exceeding quarterly earnings and revenue estimates. Tenet Healthcare, a diversified healthcare services company, reported strong financial performance with an 8.9% year-over-year revenue increase and substantial EPS guidance for FY 2026.
Tenet Healthcare (THC) EVP discloses stock and RSU holdings
Tenet Healthcare Corp EVP Michael T. Maloney filed an initial ownership report (Form 3) detailing his equity holdings as of February 27, 2026. The filing includes common stock, performance stock options, and various tranches of unvested, time-based restricted stock units. This report outlines existing holdings and vesting schedules but does not indicate any new purchases or sales by Maloney.
Saint Vincent parent company wins lawsuit over poor hospital safety grades
Tenet Healthcare Corp., the parent company of Saint Vincent Hospital, won a lawsuit against the Leapfrog Group over its hospital safety ratings. A U.S. District Judge ruled that Leapfrog's grading approach was an unfair and deceptive business practice. This decision impacts how hospital safety is assessed and reported.
Dimensional Fund Advisors LP Sells 150,154 Shares of Tenet Healthcare Corporation $THC
Dimensional Fund Advisors LP reduced its stake in Tenet Healthcare Corporation by 10.1% in the third quarter, selling 150,154 shares and holding 1,332,083 shares valued at $270,447,000. Other hedge funds also adjusted their positions in THC, with several increasing their holdings. The stock currently trades at $236.67, with a market cap of $20.58 billion, and has received a "Moderate Buy" consensus rating from analysts with an average price target of $247.67.
Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know
Shares of several healthcare companies, including Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco, plummeted after a report indicated an unexpected contraction in February employment, particularly in the healthcare sector. The Bureau of Labor Statistics reported a loss of 92,000 nonfarm payroll jobs and 28,000 healthcare positions, raising concerns among investors about a potential economic slowdown. This market reaction could present buying opportunities for high-quality stocks.
Tenet Healthcare Corp. Hits New 52-Week High of $245.98
Tenet Healthcare Corp. has achieved a new 52-week high of $245.98, demonstrating strong performance in the hospital industry with a 77.7% increase over the past year. The company boasts a high return on equity despite a significant debt-to-equity ratio and a market capitalization of USD 31,105 million. This milestone reflects robust financial management, though it does not offer a dividend yield, opting to reinvest in operations.
Tenet Healthcare to stream Barclays healthcare talk on Mar. 10
Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, at 9:30 a.m. Eastern Time. A live webcast and audio archive of the event will be accessible through the investor relations section of Tenet's website. The replay will be available for 30 days.
Tenet Healthcare Corp. Hits New 52-Week High of $247.21
Tenet Healthcare Corp. has reached a new 52-week high of $247.21, demonstrating strong performance in the hospital industry with a 75.23% one-year growth. The company, with a market capitalization of $31,105 million and a P/E ratio of 11.00, exhibits efficient profit generation despite a higher reliance on debt financing. Its return on equity is a notable 60.21%, marking a significant recovery from its previous low of $109.82.
Tenet Healthcare (THC) COO logs RSU grants, conversions and tax share disposals
Tenet Healthcare's EVP and COO, Lisa Y. Foo, reported several equity transactions including the grant of 7,520 restricted stock units and the exercise of prior RSU awards into common stock. She also disposed of shares to cover tax withholding obligations linked to vesting RSU awards. Following these transactions, Foo directly owns 42,053 shares of Tenet Healthcare common stock.
Tenet Healthcare (THC) accounting officer reports 8,017-share stock sale
Tenet Healthcare's principal accounting officer, Scott R. Ramsey, reported selling 8,017 shares of common stock on March 2, 2026, at weighted average prices between $230.98 and $233.69. Prior to the sales, on February 27, 2026, restricted stock units vested and converted into common shares, with some shares disposed of to cover tax obligations. After these transactions, Ramsey directly owns 5,892 shares of Tenet Healthcare common stock.
Tenet Healthcare (THC) CFO logs RSU award, vesting and tax share disposals
Tenet Healthcare's EVP & CFO, Sun Park, reported equity compensation activities including the grant of 7,520 time-based Restricted Stock Units (RSUs) on February 27, 2026, which vest over three years. On the same date, 4,670 RSUs from a 2024 award converted into common shares. Additionally, shares were withheld at prices of $237.58 and $239.39 to cover withholding taxes on vested performance share units and RSUs, leaving Park with a direct ownership of 19,438 Tenet Healthcare common shares.
Tenet Healthcare stock hits all-time high at 240.86 USD
Tenet Healthcare Corporation's stock reached an all-time high of $240.86, reflecting a 96.1% increase over the past year and a market capitalization of $20.93 billion. This growth is attributed to strong market performance, strategic initiatives, and favorable industry conditions. Analysts from Guggenheim, Jefferies, and KeyBanc have raised price targets following the company's impressive Q4 2025 results and positive 2026 guidance.
Quantbot Technologies LP Has $3.42 Million Position in Tenet Healthcare Corporation $THC
Quantbot Technologies LP significantly increased its stake in Tenet Healthcare Corporation (NYSE:THC) by 4,442.0% in Q3, now holding 16,851 shares valued at $3.42 million. The company recently exceeded Q4 earnings expectations with EPS of $4.70 and revenue of $5.53 billion, and analysts have set a consensus target price of $247.67 with mostly "Buy" ratings. Institutional investors own a substantial 95.44% of the stock.
Proposed sale of 24,000 shares reported by THC (NYSE: THC)
A Form 144 filing indicates a proposed sale of 24,000 common shares of Tenet Healthcare Corp (NYSE: THC), valued at approximately $5.6 million. These shares are associated with restricted stock vesting events that occurred between February 24, 2026, and March 1, 2026. The filing notes Fidelity Brokerage Services LLC as the broker for the proposed transaction, though it does not confirm the actual completion of the sale.
Tenet Healthcare Corporation $THC Stock Holdings Trimmed by Andra AP fonden
Andra AP fonden significantly reduced its stake in Tenet Healthcare Corporation (NYSE:THC) by 90.5% in the third quarter of 2025, selling 15,199 shares and retaining 1,600 shares. Despite this trim, other major institutions like Norges Bank, Boston Partners, and WCM Investment Management increased their holdings, leading to 95.44% institutional ownership. Tenet Healthcare also reported strong Q3 earnings, beating estimates with $4.70 EPS on $5.53 billion revenue, and analysts have a consensus "Moderate Buy" rating with an average $247.67 price target.
Tenet Healthcare (NYSE:THC) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Tenet Healthcare (NYSE:THC) from a "buy" to a "strong-buy" rating, reflecting positive analyst sentiment and strong quarterly results. The company exceeded EPS consensus with $4.70 and provided optimistic FY2026 guidance, leading to upward revisions in near-term estimates. The average analyst target price is $247.67, with a consensus rating of "Moderate Buy."
THC Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Tenet Healthcare Corp (THC) based on its income statement, balance sheet, and cash flow for fiscal year 2025. It highlights key metrics such as revenue, net income, EPS, and debt, along with financial health scores for profitability, growth, leverage, liquidity, cash flow, and returns. The report also includes an Altman Z-Score, Piotroski F-Score, and analysis of earnings quality and interest coverage to assess the company's overall financial stability and risk.
Tenet Healthcare (THC) EVP Arnst acquires 3,800 shares via RSU vesting
Tenet Healthcare's EVP, Chief Admin. Officer & GC, Thomas W. Arnst, acquired 3,800 shares of common stock on February 24, 2026, through the vesting of Restricted Stock Units (RSUs) granted under the 2019 Stock Incentive Plan. This transaction, reflecting a conversion at $0.00 per share, was the first of three equal annual installments. After the vesting, Arnst directly holds 41,585 shares of common stock and 7,602 restricted stock units.
